ArticleEye (London, England)2025
Does completion time of the initiation phase of anti-vascular growth factor affect visual and anatomical outcomes?: The MARMASIA study group report No.5.
Article in Eye (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo demonstrate effect of completion time of initiation phase of anti-vascular endothelial growth factor (anti-VEGF) agents on visual and anatomical outcomes in diabetic macular oedema patients.
methodsThis multicentre, retrospective, comparative study included a subgroup of patients from MARMASIA Study. Two groups were formed according to completion time of initiation phase of anti-VEGF treatment as ideal and extended completion time groups (ICT and ECT groups). Changes in best corrected visual acuity (BCVA) as ETDRS letter score, central macular thickness (CMT) were compared between the groups at 3
resultsA total of 328 eyes of 239 patients were included. Ninety-five eyes were in ICT, 233 eyes were in ECT group. Mean BCVA was significantly better than the baseline at 3
conclusionsInitiation phase injections must be completed within a maximum of 70 days (between injections 28 + 7 days) for better visual and anatomical outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.